Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program

Cancer-associated venous thromboembolism (CAT) guidelines recommend direct oral anticoagulants as alternatives to low-molecular-weight heparin (LMWH) in most patients. This study compared the effectiveness and safety of rivaroxaban versus LMWH for a broad CAT cohort. The cohort study used electronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Caroti, Kimberly Snow, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Cohen, Alexander T., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467381/
https://www.ncbi.nlm.nih.gov/pubmed/37583314
http://dx.doi.org/10.1177/10760296231189282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467381/
https://www.ncbi.nlm.nih.gov/pubmed/37583314
http://dx.doi.org/10.1177/10760296231189282

Ejemplares similares